Supplementary materials

Figure S1




Figure S1. Association between inhibitory activity of natural products against ZIKV strain PAN2016 and their cytotoxicity. ZIKV stain PAN2016 (100 PFU) was incubated with each of the natural products at different concentrations at 37°C for 1 h. The compound-virus mixtures were then transferred to Vero E6 cells (10⁵/well) and incubated at 37°C for 1 h. Plates were incubated at 37°C for 4-5 days. Viral titers at each concentration were calculated by plaque assay, which are expressed as percentage inhibition of the untreated virus (black circles). Cell viability was assessed by the Cell Counting Kit-8 (CCK8) assay, and expressed as a percentage relative to that of the untreated cells (red circles). The concentrations of natural products that inhibited 50% (IC50) or 90% (IC90) of plaque formation, or caused 50% cytotoxicity (CC50) in Vero E6 cells are shown in the figure. The data are expressed as the mean ± standard error of the mean (s.e.m.) (n=2). The experiments were repeated twice with similar results.




Figure S2. Association between inhibitory activity of natural products against ZIKV strain PRVABC59 and their cytotoxicity. ZIKV stain PRVABC59 (100 PFU) was incubated with each of the natural products at different concentrations at 37°C for 1 h. The compound-virus mixtures were then transferred to Vero E6 cells (10^5 /well) and incubated at 37°C for 1 h. Plates were further incubated at 37°C for 4-5 days. Viral titers at each concentration were calculated by plaque assay, which are expressed as percentage inhibition of the untreated virus (black circles). Cell viability was assessed by the Cell Counting Kit-8 (CCK8) assay, and expressed as a percentage relative to that of the untreated cells (red circles). The concentrations of natural products that inhibited 50% (IC50) or 90% (IC90) of plaque formation, or caused 50% cytotoxicity (CC50) in Vero E6 cells are shown in the figure. The data are expressed as the mean \pm standard error of the mean (s.e.m.) (n=2). The experiments were repeated twice with similar results.

Figure S3



R116265	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
PAN2016	NKEALVEFKDAHAKROTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
PAN2015	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
FLR	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
R103451	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
PRVABC59	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
PLCal ZV	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
IbH 30656	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	291
MEX 2-81	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDK	297
MR 766	NKEALVEFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKG <mark>K</mark> L F SGHLKCRLKMDK	293
DENV-1-V1792	RODLLVTFKTAHAKKQEVVVLGSQEGAMHTALTGATEIQTSGTT-TIFAGHLKCRLKMDK	293
DENV-2-V594	QKETLVTFKNPHAKKQDVVVLGSQEGAMHTALTGATEIQMSSGN-LLFTGHLKCRLRMDK	291
DENV-3-V1043	RKELLVTFKNAHAK <mark>K</mark> QEVVVLGSQEGAMHTALTGATE <mark>IQNSGGT-SIFA</mark> GHLKCRLKMDK	289
2211 0 12010		203
R116265	LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR	357
PAN2016	LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR	357
PAN2015	LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR	357
FLR	LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR	357
R103451	${\tt LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR}$	357
PRVABC59	LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVE <mark>L</mark> QYAGTDGPCKVPAQMAVDMQTLTPVGR	357
PLCal_ZV	${\tt LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR}$	357
IbH 30656	LRLKGVSYSLCTAAFTFTK <mark>V</mark> PAETLHGTVTVEVQYAG <mark>R</mark> DGPCKVPAQMAVDMQTLTPVGR	351
MEX 2-81	LRLKGVSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGR	357
MR 766	LRLKGVSYSLCTAAFTFTK <mark>V</mark> PAETLHGTVTVEVQYAGTDGPCK <mark>I</mark> P <mark>V</mark> QMAVDMQTLTPVGR	353
DENV-1-V1792	L <mark>T</mark> LKGMSY <mark>VM</mark> CT <mark>GS</mark> F <mark>KLE</mark> KEVAETQHGTVLVQIKYEGTDAPCK <mark>IPFSTQ</mark> -D <mark>EKGV</mark> TQNGR	352
DENV-2-V594	L <mark>Q</mark> LKGMSYSMCTGKFKIVKEIAETQHGT <mark>IVIR</mark> VQY <mark>E</mark> GDGSPCK <mark>IPFEIM</mark> -D <mark>LEKRHVL</mark> GR	350
DENV-3-V1043	L <mark>ELKGMSYAMCTNTFVLKKEVSETQ</mark> HGT <mark>ILIKVEYKGEDA</mark> PCK <mark>IPFSTE</mark> -D <mark>GQGKAHN</mark> GR	348
D445055		
R116265	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
PAN2016	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
PAN2015	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
FLR	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
R103451	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
PRVABC59	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
PLCal_ZV	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
IbH 30656	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGS <mark>I</mark> IGKAFEATVRG	411
MEX 2-81	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRG	417
MR 766	LITANPVITESTENSKMMLELDPPFGDSYIVIGVGDKKITHHWHRSGSTIGKAFEATVRG	413
DENV-1-V1792	LITANPIVTD - KEKPVNIEAEPPFGESYIVIGAGEKALKLSWFKKGSSIGKMFEATARG	410
DENV-2-V594	LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVEPGQLKLNWFKKGSSIGQMFETTMRG	408
DENV-3-V1043	LITANPV <mark>VTKKEEPVNIEAE</mark> PPFG <mark>ESN</mark> IVIG <mark>IGDNALKINWYKK</mark> GS <mark>S</mark> IGKMFEAT <mark>A</mark> RG	406
	<	
R116265	AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL	477
PAN2016	AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL	477
PAN2015	AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL	477
FLR	AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL	477
R103451	AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL	477
PRVABC59	AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL	477
PLCal ZV	AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL	477
IbH 30656	AKRMAVLGDTAWDFGSVGG <mark>VF</mark> NSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLL <mark>V</mark> WLGL	471
MEX 2-81	${ t AKRMAVLGDTAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGL}$	477
MR 766	AKRMAVLGDTAWDFGSVGG <mark>VF</mark> NSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLL <mark>V</mark> WLGL	473
DENV-1-V1792	a <mark>r</mark> rma <mark>i</mark> lgdtawdfgs <mark>i</mark> gg <mark>vftsv</mark> gk <mark>lv</mark> hqifg <mark>taygv</mark> lfsg <mark>v</mark> sw <mark>tmk</mark> igigvll <mark>t</mark> wlgl	470
DENV-2-V594	AKRMA <mark>I</mark> LGDTAWDFGS <mark>L</mark> GG <mark>VFTS</mark> IGK <mark>ALHQV</mark> FGA <mark>IYGAA</mark> FSGVSW <mark>TMK</mark> ILIG <mark>VIITWI</mark> GM	468
DENV-3-V1043	ARRMA <mark>I</mark> LGDTAWDFGSVGG <mark>V</mark> LNSLGK <mark>MV</mark> HQIFG <mark>S</mark> AYTALFSG <mark>V</mark> SW <mark>VMK</mark> IGIG <mark>V</mark> LL <mark>TWI</mark> GL	466
R116265	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
PAN2016	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
PAN2015	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
FLR	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
R103451	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
PRVABC59	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
PLCal_ZV	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
IbH 30656	NTKNGSISL <mark>T</mark> CLALGGV <mark>M</mark> IFLSTAVSA 498	
MEX 2-81	NTKNGSISLMCLALGGVLIFLSTAVSA 504	
MR 766	NTKNGSISL <mark>T</mark> CLALGGV <mark>M</mark> IFLSTAVSA 500	
DENV-1-V1792	NSRSTSLSMTCIAVGLVTLYLGVMVQA 497	
DENV-2-V594	NSRSTSLSVSLVLVGVVTLYLGVMVQA 495	
DENV-3-V1043	N <mark>SKNTSMSFSCIAI</mark> G <mark>VITLY</mark> L <mark>GAV</mark> VQA 493	

Figure S3. Multiple sequence alignment of amino acid (aa) sequences of E protein of 10 ZIKV strains and DENV-1-3 human strains used in this study. Schematic maps of ZIKV polyprotein and ZIKV E protein are listed on top of the alignment. Amino acids variable positions are highlighted. The sequence of DENV-4-PR 06-65-740 is not available, so its sequence alignment is not included. The alignment was performed using Clustal V method of MegAlign (v7.1) within the DNASTAR package. C: capsid; prM: precursor of membrane; E: envelope; NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5: nonstructural proteins. DI-DIII: domain I-III of E protein; FL: fusion loop; S: stalk region; TM: transmembrane domain.